SEC Tracker
Get the app
PKTX · XBRL financial data

ProtoKinetix financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (PKTX's year ends in late December)

In thousands of dollarsMar 31, 2023Jun 30, 2023Sep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025
Research and development23322136*37212121*34242424*
General and administrative33361715*14131618*15141613*
Total operating expenses10711680112*928585103*989185120*
Income tax expense (benefit)———year only———year only———year only
Net income (loss)(107)(116)(80)(112)*(92)(85)(85)(103)*(98)(91)(85)(120)*
Earnings per share, basic USD per share(0.01)(0.01)(0.01)0.00*(0.01)0.000.000.00*0.000.000.000.00*
Earnings per share, diluted USD per share(0.01)(0.01)(0.01)0.00*(0.01)0.000.000.00*0.000.000.000.00*
Weighted average shares, basic thousands of shares325,458335,630335,630335,554*333,103353,972364,850381,980*374,148353,972389,450426,954*
Weighted average shares, diluted thousands of shares325,458335,630335,630335,554*333,103353,972364,850381,980*374,148353,972389,450426,954*

Balance sheet

CSV

Fiscal quarters (PKTX's year ends in late December)

In thousands of dollarsMar 31, 2023Jun 30, 2023Sep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025
Cash and cash equivalents7191220326549011
Total current assets8201321437—————
Total assets447467451481461474479466529474478483
Accounts payable53131345685988124152149227185
Total current liabilities53131345685988124152149227185
Accumulated deficit(47,556)(47,671)(47,751)(47,864)(47,956)(48,041)(48,126)(48,228)(48,326)(48,417)(48,502)(48,622)
Total stockholders' equity394454438436394415392342376325250298
Total liabilities and equity447467451481461474479466529474478483
Common shares outstanding (cover page) thousands of shares327,880335,630338,880346,713352,880364,980366,980377,580388,580389,080391,580411,630

Cash flows

CSV

Fiscal quarters (PKTX's year ends in late December)

In thousands of dollarsMar 31, 2023Jun 30, 2023Sep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025
Net income (loss)(107)(116)(80)(112)*(92)(85)(85)(103)*(98)(91)(85)(120)*
Stock-based compensation——00*——14*——00*
Net cash from operating activities(85)(144)*(70)*(77)*(58)(81)*(39)*(45)*(52)(80)*(4)*1*
Net cash from investing activities(14)(20)*(1)*(25)*(10)(26)*(17)*(5)*(26)(5)*(6)*(20)*
Proceeds from issuing common stock80175*65*(69)*50106*60*40*13236*10*20*
Net cash from financing activities80175*65*110*50106*60*40*13236*10*20*

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
ProtoKinetix1.1not reported0.6*411.6M— 10-KDec 31, 2025
Galera Therapeutics5,500not reported(875)160.4M6.3 quarters 10-QMar 31, 2026
Agentix0not reported(26)40.1M0.0 quarters 10-QJun 30, 2026
Decoy Therapeutics8,289228(2,652)*655,1853.1 quarters 10-QJun 30, 2026
Nomad Power Solutions12,670not reported(1,612)*16.1M7.9 quarters 10-QJun 30, 2026
Evofem Biosciences2852,633(3,140)*132.5M0.1 quarters 10-QJun 30, 2026
Regen BioPharma0.259(24)*1.7B0.0 quarters 10-QJun 30, 2026
Twinlab Consolidated Holdings13not reported(907)*259.1M0.0 quarters 10-KDec 31, 2024
Cannapharmarx0.6276(127)*708.7M0.0 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.